Cancer News and Research

Latest Cancer News and Research

Gottlieb collaborates with Loyola Cancer Care to deliver world class university hospital expertise

Cancer patients at the Marjorie G. Weinberg Cancer Center, located on the Gottlieb Memorial Hospital campus, are now being seen by Loyola University Health System physicians.Loyola Cancer Care & Research at the Marjorie G. Weinberg Cancer Center offers patients the convenience of a community hospital and the expertise of a world-class university hospital.

28 Jul 2010

CPRIT awards UH $2.4 million for new multidisciplinary research

The University of Houston (UH) received a $2.4 million grant to fund the most promising young cancer researchers who are working at the cutting-edge of a new multidisciplinary approach to fighting cancer.The award is part of the latest round of grant disbursements from the Cancer Prevention and Research Institute of Texas (CPRIT), which oversees the state's new billion-dollar war on cancer. It is UH's second CPRIT grant, and the first in the science and engineering fields.

28 Jul 2010

SurModics, EGEN continue collaboration on long-term controlled release of siRNA complexes

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry and EGEN, Inc., a privately held biopharmaceutical company focused on developing nucleic acid (DNA and RNAi) therapeutics for the treatment of human diseases, are pleased to announce they have executed a continuation of their feasibility collaboration focused on long-term controlled release of siRNA complexes.

28 Jul 2010

CTC is not cost effective compared with colonoscopy: Study

A UNC physician authored an editorial in the July 27 online issue of the Journal of the National Cancer Institute (JNCI) commenting on results of an analysis of the cost effectiveness of colonoscopy versus computed tomographic colonography (CTC).The cost effectiveness analysis concluded that CTC or virtual colonoscopy is not cost effective compared with colonoscopy if reimbursed at the same rate as colonoscopy

28 Jul 2010

What steps should be taken when medicine can't save a life?

Writing for The New Yorker, Atul Gawande explores the central medical issues involved in treating patients with terminal conditions. He asks the question: "[I]f you were the one who had metastatic cancer—or, for that matter, a similarly advanced case of emphysema or congestive heart failure—what would you want your doctors to do? The issue has become pressing, in recent years, for reasons of expense.

28 Jul 2010

Morphine blocks new blood vessel and tumor growth: Study

Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the August 2010 issue of the American Journal of Pathology.

28 Jul 2010

Scientists identify genetic variants for breast cancer

Women with higher risk scores that consisted of having certain genetic variants most strongly linked to breast cancer had an associated higher risk of breast cancer, with these scores also highly predictive of estrogen receptor-positive disease, according to a study in the July 28 issue of JAMA.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Genzyme Corp.today said it welcomed the Centers for Medicare and Medicaid Services' decision not to include oral medications without IV equivalents in Medicare's End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme's Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014.

28 Jul 2010

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells.

28 Jul 2010

National health campaigns make men less likely to choose cancer screening: Study

In Germany, several national health campaigns promote cancer screening by announcing that only one in five German men gets screened. This is supposed to motivate men to have an examination. But a new study published in Psychological Science, a journal of the Association for Psychological Science, finds that this well-meaning message has the exact opposite effect: it makes men less likely to choose to get screened.

28 Jul 2010

GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib

The National Comprehensive Cancer Network has been awarded two individual $2 million grants from GlaxoSmithKline to support clinical studies of ofatumumab (Arzerra®, GlaxoSmithKline) in the treatment of hematologic malignancies and pazopanib (Votrient®, GlaxoSmithKline) in the treatment of solid tumors.

28 Jul 2010

LLS collaborates with Shape Pharmaceuticals to advance treatment for CTCL

The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development. The compound, SHP-141, is a first-in-class topical histone deacetylase inhibitor with the potential to treat both early- and late-stage CTCL.

28 Jul 2010

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.

28 Jul 2010

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Using chemical "nanoblasts" that punch tiny holes in the protective membranes of cells, researchers have demonstrated a new technique for getting therapeutic small molecules, proteins and DNA directly into living cells.Carbon nanoparticles activated by bursts of laser light trigger the tiny blasts, which open holes in cell membranes just long enough to admit therapeutic agents contained in the surrounding fluid. By adjusting laser exposure, the researchers administered a small-molecule marker compound to 90 percent of targeted cells - while keeping more than 90 percent of the cells alive.

28 Jul 2010

Cancer survivor to celebrate 100th birthday

Loyola University Hospital cancer patient Mary Cipolla was 89 years old when she underwent one of the most extensive operations in surgery, known as the Whipple procedure.

28 Jul 2010

CIHR grants $2.5 million to probe impact of physical activity on breast cancer

Over the next five years, a diverse, multi-disciplinary team of researchers led by Dr. Kerry Courneya of the University of Alberta and Dr. Christine Friedenreich of Alberta Health Services will conduct a series of five large research projects to probe the impacts of physical activity on breast cancer thanks to a $2.5 million team grant over five years from the Canadian Institutes of Health Research (CIHR).

28 Jul 2010

Analyzing PSA level not sufficient for treatment decisions: Report

A new report published in the July 26 issue of Archives of Internal Medicine claims many men who are diagnosed with prostate cancer undergo aggressive therapy, even when they have low PSA scores and low-risk disease, saying "these results underscore the fact that PSA level, the current biomarker, is not a sufficient basis for treatment decisions."

28 Jul 2010

BioImagene collaborates with ten new academic medical centers to develop digital pathology solutions

BioImagene, Inc., the leading provider of innovative digital pathology solutions has added ten new academic medical centers to its roster of collaborators during the last quarter. Many of these collaborators have been named "America's Best Hospitals 2010-2011: The Honor Roll" by U.S. News and World Report.

28 Jul 2010

Cancer News and Research

Latest Cancer News and Research

Gottlieb collaborates with Loyola Cancer Care to deliver world class university hospital expertise

CPRIT awards UH $2.4 million for new multidisciplinary research

SurModics, EGEN continue collaboration on long-term controlled release of siRNA complexes

CTC is not cost effective compared with colonoscopy: Study

What steps should be taken when medicine can't save a life?

Morphine blocks new blood vessel and tumor growth: Study

Scientists identify genetic variants for breast cancer

Regeneron second-quarter total revenues increase to $115.9 million

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

National health campaigns make men less likely to choose cancer screening: Study

GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib

LLS collaborates with Shape Pharmaceuticals to advance treatment for CTCL

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Cancer survivor to celebrate 100th birthday

CIHR grants $2.5 million to probe impact of physical activity on breast cancer

Analyzing PSA level not sufficient for treatment decisions: Report

BioImagene collaborates with ten new academic medical centers to develop digital pathology solutions

Industry Focus eBook - Oncology (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in